278 related articles for article (PubMed ID: 22553355)
1. Smoothened antagonists reverse taxane resistance in ovarian cancer.
Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
Steg AD; Burke MR; Amm HM; Katre AA; Dobbin ZC; Jeong DH; Landen CN
Oncotarget; 2014 Aug; 5(16):7065-80. PubMed ID: 25216523
[TBL] [Abstract][Full Text] [Related]
3. The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
Zhang H; Hu L; Cheng M; Wang Q; Hu X; Chen Q
Oncol Rep; 2020 Dec; 44(6):2610-2620. PubMed ID: 33125122
[TBL] [Abstract][Full Text] [Related]
4. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.
Steg AD; Katre AA; Goodman B; Han HD; Nick AM; Stone RL; Coleman RL; Alvarez RD; Lopez-Berestein G; Sood AK; Landen CN
Clin Cancer Res; 2011 Sep; 17(17):5674-85. PubMed ID: 21753153
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
6. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN
PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925
[TBL] [Abstract][Full Text] [Related]
7. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
9. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Duran GE; Sikic BI
PLoS One; 2019; 14(1):e0210879. PubMed ID: 30668583
[TBL] [Abstract][Full Text] [Related]
10. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
[TBL] [Abstract][Full Text] [Related]
11. Smoothened as a new therapeutic target for human osteosarcoma.
Hirotsu M; Setoguchi T; Sasaki H; Matsunoshita Y; Gao H; Nagao H; Kunigou O; Komiya S
Mol Cancer; 2010 Jan; 9():5. PubMed ID: 20067614
[TBL] [Abstract][Full Text] [Related]
12. Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.
Arnhold V; Boos J; Lanvers-Kaminsky C
Cancer Chemother Pharmacol; 2016 Mar; 77(3):495-505. PubMed ID: 26781311
[TBL] [Abstract][Full Text] [Related]
13. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK
Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
16. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E
Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355
[TBL] [Abstract][Full Text] [Related]
17. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
18. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
Blotta S; Jakubikova J; Calimeri T; Roccaro AM; Amodio N; Azab AK; Foresta U; Mitsiades CS; Rossi M; Todoerti K; Molica S; Morabito F; Neri A; Tagliaferri P; Tassone P; Anderson KC; Munshi NC
Blood; 2012 Dec; 120(25):5002-13. PubMed ID: 22821765
[TBL] [Abstract][Full Text] [Related]
19. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
Stordal B; Hamon M; McEneaney V; Roche S; Gillet JP; O'Leary JJ; Gottesman M; Clynes M
PLoS One; 2012; 7(7):e40717. PubMed ID: 22792399
[TBL] [Abstract][Full Text] [Related]
20. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
Galimberti F; Busch AM; Chinyengetere F; Ma T; Sekula D; Memoli VA; Dragnev KH; Liu F; Johnson KC; Guo Y; Freemantle SJ; Andrew AS; Greninger P; Robbins DJ; Settleman J; Benes C; Dmitrovsky E
Int J Oncol; 2012 Nov; 41(5):1751-61. PubMed ID: 22923130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
